Virtual event, Worldwide : 16 - 17 February 2021
Wednesday 17 February, 15:35-16:05 CET
Speaker: Noel F.C.C de Miranda, Leiden University Medical Centre, Netherlands
"Spatial immunophenotyping of colorectal cancers by imaging mass cytometry"
For more information, click here
Although great strides have been made in cancer treatments in the past two decades, many cancers remain resistant to currently available treatments. New approaches are needed.
Drugs that utilize a patient’s immune system (immunotherapies) have great potential, but this promising approach is largely unfulfilled because of the complexity of the human immune system and how it reacts to the presence of cancer cells.
To develop successful immunotherapies, there is a pressing need to better understand the immune states of a patient before, during and after treatment. Monitoring a patient’s immune state is a complex task requiring measurement of many different immune cell types, with each cell potentially expressing a large and ever-changing number of molecular markers that are important in targeting and eliminating cancer cells.
Gathering this information provides better ways to treat patients based on their unique immunologic fingerprints, resulting in more positive outcomes for patients in clinical trials and improvements in matching patients to the best therapies. Unfortunately, clinical researchers have not had adequate tools to quickly, efficiently and reproducibly gather the large amount of data needed to more completely assess a patient’s immune status.
To overcome this insufficiency, Fluidigm has commercialized a cell analysis platform uniquely capable of measuring the most molecular markers per cell in a single blood sample of any cytometry (cell measurement) system currently available.
The Helios™ mass cytometer enables researchers to obtain an immune fingerprint reflecting the state of a patient’s immune system at any given point in time. This type of immune monitoring can allow physicians to determine whether an immunotherapy or other treatment is working. It can also provide insights needed to develop new therapies. With the addition of the Hyperion™ Tissue Imager module, Helios can measure these same molecular markers in a patient’s tissue or tumor at specific locations that can be relevant to treatment.
Other immune cell analysis technologies struggle to quickly and reliably detect an equally large number of targets in a single patient sample and can suffer from loss of signal, lack of reproducibility and data flaws caused by signal interference. Fluidigm mass cytometry-based technologies leverage unique and proprietary methods to generate the highest-quality data across the largest number of targets in a single patient sample.
This widely accepted technology has impacted many areas of disease research including COVID-19 and other infectious disease, cancer, diabetes, arthritis, autoimmune disorders and cardiovascular disease, as proven in more than 1,000 scientific publications in the past 10 years and in over 100 clinical research trials. Notably, the Helios mass cytometer was adopted by 2018 Nobel Prize winner Jim Allison as a key technology for immunotherapy research at MD Anderson Cancer Center.
Fluidigm platforms are regularly used in clinical trials and drug development by major cancer research hospitals and clinical research institutes as well as by all major pharmaceutical companies. Their use by the medical research community will continue to have a positive impact on health care now and in the future.
Senior Market Development Manager
Regional Sales Manager
If you see a 'Let's chat' icon on the bottom right of the page, it means that a representative is online and ready to chat and answer your questions! Click on the icon to chat with them.
If you see a 'Send message' button it means nobody is online right now, but you can send an email instead.
Dietary requirements (in-person events only)
Please indicate any special dietary requirements here. We will try to cater to all dietary requirements and we will write to you if there is any problem.
Sharing your details with others
Please click below if you agree we can share your name, email and postal address with participants and exhibitors, who may use them to contact you.
Please note: you have selected NOT to share your details with participants and exhibitors.
You can click above to change this.
We will use the email address in your EACR account to communicate with you. However, during the checkout process you will need to enter the name and contact details of the person paying for your registration, if this is different to your own details. Please make sure you have this information to hand.
Terms and Conditions
Please read our Membership and Events Terms and Conditions before completing your registration.
Photography and video
Please note that we will be taking photographs and video at the conference for publicity and marketing purposes. If you do not wish to take part please inform the photographer.
The EACR is grateful for the continued support of its Industry Partners: